STAT July 15, 2024
Jason Mast

Lexeo Therapeutics said Monday that a gene therapy designed to prevent fatal cardiac complications of a genetic disorder called Friedrich’s ataxia reduced signs of heart disease in a handful of patients.

The data are very early and less-than-clear-cut. But given a top Food and Drug Administration official’s recent efforts to advance gene therapies under accelerated approval — most notably, with the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
New 'how-to guide' for future rapid vaccine development
Infographic: R&D Spending Growth of Top Pharma Companies
Medicare prescription drug pricing variance: 5 things to know
Payer group 'deeply concerned' by Medicare weight loss drug coverage proposal
Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Share This Article